Nivolumab
Nivolumab fails to extend PFS in glioblastoma subset
Nivolumab regimen ‘highly active’ in relapsed/refractory primary mediastinal large B-cell lymphoma
Immunotherapy effective for many patients ineligible for registration trials, but caution necessary
FDA grants breakthrough therapy designation to NKTR-214 in combination with Opdivo for advanced melanoma
Multidisciplinary approach, persistence key in treating renal cell carcinoma
New data may change treatment paradigm for metastatic renal cell carcinoma
In 2017, the positive results of two trials — CheckMate-214 and CABOSUN — garnered a great deal of attention and discussion, and prompted many in the field to claim that a revolution is underway in the management of patients with metastatic renal cell carcinoma. To better understand the implications of these trials, Healio spoke with Neeraj Agarwal, MD, director of the genitourinary oncology program and associate professor of medicine at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, who discussed the key findings, and shared his thoughts on how the landscape of metastatic renal cell carcinoma therapies may change in the coming years.